Last Price$79.10NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/17/19

Today's Change+0.76(0.97%)
Bid (Size)$74.00 (1)
Ask (Size)$80.00 (1)
Day Low / High$77.57 - 79.37
Volume970.8 K

Incyte, Eli Lily Say Baricitinib for Atopic Dermatitis Meets Targets in Late-Stage Trial

4:00PM ET 8/23/2019 MT Newswires
Incyte (INCY) and Eli Lilly (LLY) said on Friday a late-stage trial of baricitinib to treat moderate to severe atopic dermatitis (AD) in adults has met its primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.

Adding baricitinib to standard-of-care topical corticosteroids significantly improved disease severity, they said. Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries.

Price: 81.91, Change: -3.65, Percent Change: -4.27